INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy.

Hussain, S.A., Oughton, J.B. orcid.org/0000-0002-2047-804X, Smith Whelan, R. et al. (9 more authors) (2024) INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy. In: 2024 ASCO Genitourinary Cancers Symposium, 25-27 Jan 2024, San Francisco, CA.

Metadata

Item Type: Conference or Workshop Item
Authors/Creators:
Dates:
  • Published (online): 29 January 2024
  • Published: 1 February 2024
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 09 Jul 2025 12:16
Last Modified: 09 Jul 2025 12:16
Published Version: https://ascopubs.org/doi/10.1200/JCO.2024.42.4_sup...
Status: Published
Publisher: American Society of Clinical Oncology (ASCO)
Identification Number: 10.1200/jco.2024.42.4_suppl.tps710
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)